Decoding the therapeutic potential of infant bacteria
Discover how we harness the unique potential of infant gut bacteria to develop groundbreaking therapies. Explore our scientific methodologies, key discoveries, and the innovative pipeline transforming healthcare.
The benefits of microbe-derived therapies
Immune system reprogramming
Our therapies use the unique properties of infant gut bacteria to programme the immune system, boosting its ability to combat diseases.
Endocrine function direction
By directing endocrine function, microbes influence hormones, neurotransmitters, and growth factors to improve health outcomes.
Metabolism regulation
Gut bacteria can regulate metabolism, addressing energy production and metabolic disorders, offering new hope for chronic disease management.
Our scientific exploration
Evaluate potential with screening and identification
Using high-throughput wet lab screens, we identify active ingredients that show promise in targeting specific pathways. This process involves a series of biochemical assays and biophysical analyses designed to evaluate the interaction of these compounds with specific biological targets, ensuring we select the most effective compounds for validation.
We start with isolation and characterisation
We isolate novel compounds from the largest infant microbe genome database and proprietary collection of infant bacteria strains in the world. Complete genomic characterisation allow us to identify unique microbial active compounds and novel bioactive molecules that are crucial for therapeutic efficacy.
And move our most promising compounds into pre-clinical validation and optimisation
Promising compounds identified through HTS are then subjected to rigorous pre-clinical validation. By focusing on mechanism-driven pathways, we can better understand how these compounds exert their therapeutic effects at a molecular level to develop therapies that offer unparalleled potential in treating chronic diseases.
Learn more about our research
Explore our collection of research publications and discover the science, latest findings, and advancements behind our innovative therapeutics.
Featured downloads
Our leading immuno-oncology candidate BIOS-001
BIOS-001, a groundbreaking therapeutic compound derived from our proprietary infant gut bacteria strains, is at the forefront of our pipeline. It has shown remarkable promise in pre-clinical studies, particularly in treating breast cancer. This candidate exemplifies our commitment to harnessing the power of infant microbes to develop life-changing therapies.
Immune system modulation
BIOS-001 enhances CD8+ T cell activity by activating gut dendritic cells, significantly boosting the immune system’s ability to target and destroy cancer cells.
Synergistic efficacy
In combination with existing treatments such as chemotherapy and immune checkpoint inhibitors, BIOS-001 has demonstrated enhanced therapeutic effects, leading to greater tumour reduction.
Robust pre-clinical validation
Extensive pre-clinical research has confirmed the efficacy of BIOS-001, paving the way for its advancement into clinical trials.
Our timeline provides a visual representation of the stages our products undergo, highlighting key milestones and upcoming advancements in our research.
BIOS-001
Discovery
Pipeline
BIOS-003
Breast cancer
($32bn market)
Novel chronic disease indication
($16bn market)
Candidate
Pre-clinical
BIOS-002
Phase 1
BIOS-001
BIOS-002
IND-enabling
Contact us
Interested in learning more about our groundbreaking work or connecting with our team? Whether you’re a publisher, potential investor, or professional eager to join us, we’d love for you to reach out and explore how we can collaborate to revolutionise healthcare through microbiome science.
Email
invest@bioscopic.co
Media enquiries
media@bioscopic.co
Careers
work@bioscopic.co
Quadram Institute Research Park
Rosalind Franklin Rd, Norwich NR4 7UQ